A utoimmune type 1 diabetes spontaneously develops in nonobese diabetic (NOD) mice and is characterized by T-cell infiltration (insulitis) followed by a progressive destruction of pancreatic islet ␤-cells. Current evidence suggests that immune dysregulation leading to defective regulatory T-cell function elicits type 1 diabetes (1, 2) . In NOD mice, effector CD4
ϩ T-cells of type 1 diabetes are Th1 cells, and regulatory CD4
ϩ T-cells may include Th2 cells (2) (3) (4) . The deficiency in interleukin (IL)-4 production by T-cells mediates immune dysregulation and was proposed to be a causal factor of type 1 diabetes in NOD mice (2, 5) . Murine IL-4 restores normal NOD T-cell proliferative responsiveness in vitro (1, 2, 5) , and anti-CD28 and IL-4 treatments protect NOD mice from type 1 diabetes (1, 2, 6) . Despite this and other evidence for a role of IL-4 secreting Th2 cells in protection against type 1 diabetes (7-9), a "protective" role for Th2 cells has not been demonstrated (3) . Other regulatory T-cell subsets, including CD4 ϩ
CD25
ϩ T-cells and invariant natural killer T-cells (iNKT cells) also mediate protection from type 1 diabetes (10 -14) .
iNKT cells are identified by the coexpression of an invariant T-cell receptor (TCR) and various natural killer (NK) cell-related surface markers, including NK1.1, high levels of cytokine (IL-4, interferon [IFN]-␥) production upon activation, and the recognition of glycolipid molecules bound to the nonclassic major histocompatibility complex (MHC) class I molecule CD1d (13, 14) . TCR-␣ chains expressed by iNKT cells consist of V␣14-J␣18 gene segments and exhibit a strong bias for V␤8.2 followed by V␤2 and V␤7 in mice. Although the natural ligands recognized by iNKT cells remain unknown, the synthetic glycosphingolipid ␣-galactosylceramide (␣-GalCer) isolated from Agelas mauritanius marine sponges can activate iNKT cells. Upon activation with ␣-GalCer, iNKT cells can regulate susceptibility to autoimmune disease and tumor surveillance (13, 14) .
We and others (13) (14) (15) (16) (17) (18) have shown that deficiencies in iNKT cell number and function mediate the development of type 1 diabetes in NOD mice and that ␣-GalCer-induced iNKT cell activation corrects these deficiencies and reduces the incidence of spontaneous and recurrent type 1 diabetes in these mice. The latter protection from type 1 diabetes is associated with a polarized Th2 milieu marked by elevated IL-4 and IL-10 and reduced IFN-␥ levels in the spleen and pancreas as well as increased IL-10R transcription in the spleen (15, 16) . Neutralization of IL-10 activity by an anti-IL-10R mAb treatment in vivo abrogates the protective effect of ␣-GalCer in cyclophosphamide (CY)-induced type 1 diabetes (15) . Administration of anti-IL-4 and anti-IL-10 mAbs blocks protection from type 1 diabetes afforded by adoptive transfer of TCR ϩ CD4 Ϫ CD8 -thymocytes containing iNKT cells (19) . While these observations suggest that protection from type 1 diabetes by ␣-GalCer is mediated by IL-10 and/or IL-4, the mechanism(s) of iNKT cell regulation of susceptibility to type 1 diabetes remains unknown (14) .
Here we use NOD.IL-4 -/-and NOD.IL-10 -/-mice to show that IL-4 but not IL-10 mediates protection against spontaneous type 1 diabetes, recurrent type 1 diabetes, and prolonged syngeneic islet graft function by ␣-GalCeractivated iNKT cells. Thus, we have identified an important role for IL-4 in the protection against spontaneous and recurrent type 1 diabetes by ␣-GalCer-activated CD1d-restricted iNKT cells.
RESEARCH DESIGN AND METHODS
NOD/Del and NOD.Scid mice were bred in a specific pathogen-free barrier facility at The Robarts Research Institute (London, ON, Canada). Insulitis and type 1 diabetes are detectable by 4 -6 weeks and 4 -6 months of age, respectively, in our colony of female NOD mice. The incidence of type 1 diabetes in this colony is 25-30% at 15 weeks of age and Ͼ80% by 25 weeks. NOD.IL-4 -/-and NOD.IL-10 -/-mice were obtained from The Jackson Laboratory (Bar Harbor, ME), and their knockout phenotypes were confirmed by PCR typing (20) . Assessment of diabetes. Mice were monitored for type 1 diabetes by measurement of blood glucose levels (BGLs) twice weekly using a Glucometer (Bayer, Toronto, ON). NOD mice that displayed BGL Ͼ11.1 mmol/l on two consecutive readings were indicative of the onset of type 1 diabetes. CY-induced diabetes. Pre-diabetic (8 -9 weeks old) female NOD and NOD.IL10 -/-mice were injected intraperitoneally with CY (200 mg/kg) (Sigma, St. Louis, MO) on day 0 and day 10. Diabetes onset was monitored every other day for 30 days postinjection. Adoptive cell transfer. NOD and NOD.IL10 -/-mice (12-13 weeks old) were treated with ␣-GalCer or vehicle on days 0, 2, 4, 6, and 8. Spleens were collected on day 10, and spleen single-cell suspensions were prepared. Splenocytes (1 ϫ 10 7 cells) pooled from each group (n ϭ 5 mice) were transferred intraperitoneally to 5-to 6-week-old NOD.Scid recipient mice (15) . Detection of iNKT cells by flow cytometry. NOD mice (9 -10 weeks old) were treated with ␣-GalCer or vehicle (kindly supplied by Kirin Brewery Co., Gunma, Japan) on days 0, 2, 4, 6, and 8, as described (15) . Tissues were collected on day 10, and spleen and pancreatic lymph node (PLN) single-cell suspensions were prepared. Cells (1 ϫ 10 6 ) were treated (15 min, 4°C) with an anti-Fc␥R mAb (Clone 2.4G2, BD Pharmingen, San Diego, CA) and then stained (20 min, 23°C) with an anti-TCR-␤ mAb (Clone H57-597, BD Pharmingen) and empty or ␣-GalCer-loaded CD1 tetramers (kind gift from Dr. M. Kronenberg, La Jolla Institute for Allergy and Immunology, San Diego, CA). Flow cytometry analyses were conducted using a FACSCalibur and CELLQuest software (BD Biosciences, San Jose, CA). The specificity of staining in all tissues was verified by examining tissues from NOD.CD1d Ϫ/Ϫ mice. Treatment of mice with ␣-GalCer. For protection against spontaneous type 1 diabetes, 10-week-old NOD, NOD.IL-4 -/-, and NOD.IL-10 -/-mice were treated with ␣-GalCer (5 g/dose) every other day for five doses and then boosted at 13-14 weeks of age. For protection against CY-induced diabetes in NOD and NOD.IL-10 -/-mice, ␣-GalCer (5 g/dose) or vehicle was injected intraperitoneally on days 0, 2, 4, 6, and 8 after CY challenge. For islet transplantation, islet graft recipients were treated with ␣-GalCer (5 g/dose) on days Ϫ1, 2, 7, 14, and 21, as reported (15) . Islet transplantation. Pancreatic islets were isolated from 3-to 4-week-old male NOD mice by collagenase digestion and discontinuous density gradient purification. After overnight culture, islets (n ϭ 400) were transplanted to the renal subcapsular space of newly (Ͻ7 days) diabetic (spontaneous or CYinduced) female NOD mice (15) . cDNA array analysis. Total RNA was extracted from PLNs of ␣-GalCer-or vehicle (5 g/dose)-treated NOD, NOD.IL-4 -/-, and NOD.IL-10 -/-mice using a RNeasy mini kit (Qiagen). Aliquots of RNA (2 g ) were used to analyze gene expression using a mouse inflammatory cytokine and receptors GEArray (SuperArray), as described (21) . Relative amounts of mRNA transcripts were quantitated using a Molecular Imager System and Molecular Analyst imaging software (BioRad, Hercules, CA) and were estimated by comparing their signal intensities with the signal derived from GAPDH and ␤-actin. At least a twofold change in signal intensity from two separate experiments was considered significant, as described (21) . Statistical analysis. Statistical analyses were performed using the Student's t test (for analyses of NKT cell frequency) and the log rank test (for type 1 diabetes incidence and islet transplantation). P values Յ0.05 were considered to be statistically significant.
RESULTS
␣-GalCer protection against spontaneous type 1 diabetes is mediated by IL-4. Modulation of iNKT cells by ␣-GalCer reduces the incidence of spontaneous type 1 diabetes in NOD mice even when administered after the onset of invasive insulitis (15, 16) . We therefore investigated whether ␣-GalCer treatment initiated at 10 weeks of age protects against spontaneous type 1 diabetes in NOD.IL-4 -/-and NOD.IL-10 -/-mice. Consistent with our previous report (15) , ␣-GalCer induced protection against type 1 diabetes in NOD mice compared with vehicletreated mice (P Ͻ 0.05), as the incidence of spontaneous type 1 diabetes was reduced from 80 to 42% at 32 weeks of age (Fig. 1A) . However, the incidence of type 1 diabetes in ␣-GalCer-treated NOD.IL-4 -/-mice was not significantly reduced compared with vehicle-treated NOD.IL-4 -/-mice (85 vs. 65%, P Ͼ 0.05). ␣-GalCer-treated NOD.IL-10 -/-mice did not develop type 1 diabetes during 15-25 weeks of age, when colitis is evident in these mice (our unpublished observations). These data suggest that prevention of spontaneous type 1 diabetes by ␣-GalCer is mediated by IL-4 and not IL-10. 
iNKT PROTECTION FROM TYPE 1 DIABETES BY IL-4
␣-GalCer protects against CY-induced type 1 diabetes in NOD.IL-10 -/؊ mice. Previously, we reported that ␣-GalCer-mediated protection against CY-induced type 1 diabetes is associated with the ability of splenocytes from CY-challenged and ␣-GalCer-treated female NOD mice to secrete more IL-4 and IL-10 and less IFN-␥ than splenocytes from vehicle-treated mice upon in vitro restimulation with ␣-GalCer (15). To further evaluate the significance of increased IL-10 levels induced upon iNKT cell activation, as NOD.IL-10 -/-mice spontaneously develop colitis starting at 12-15 weeks of age, we investigated whether NOD mice deficient in IL-10 expression are protected from CY-induced type 1 diabetes upon treatment with ␣-GalCer. Consistent with our previous study, Fig. 2A shows that ␣-GalCer treatment protects from CY-induced type 1 diabetes in NOD mice, with the incidence of type 1 diabetes being 35% in ␣-GalCer-treated NOD mice and 75% in vehicle-treated NOD mice (P Ͻ 0.01), respectively. NOD.IL-10 -/-mice were also protected against CY-induced type 1 diabetes (P Ͻ 0.01) (Fig. 2B) , and the level of protection exceeded that detected in NOD wild-type ( Fig.  2A) mice (P Ͻ 0.01). ␣-GalCer treatment did not protect from type 1 diabetes in NOD.CD1d -/-mice, which are deficient in iNKT cells (Fig. 2C ). An adoptive transfer model of type 1 diabetes was also used to test the role of IL-10 in the development of type 1 diabetes upon iNKT cell activation. Similar to our previous report that spleen cells from ␣-GalCer-treated NOD mice have a diminished capacity to transfer type 1 diabetes to NOD.Scid mice (15), spleen cells from NOD.IL-10 -/-mice harvested 2 weeks after ␣-GalCer treatment also demonstrated a reduced capacity to transfer type 1 diabetes (Fig. 3A and B) . Thus, in contrast to the requirement for IL-4 in GalCer-mediated protection against type 1 diabetes, IL-10 does not appear to be required for this protection. ␣-GalCer-induced prolongation of syngeneic islet graft depends on the activity of IL-4 but not IL-10. Prolongation of pancreaticoduodenal graft survival in nonrecurrent spontaneous diabetic BB rats is associated with the proliferation of donor-derived iNKT cells in hepatic and splenic tissues and higher serum levels of IL-4 (22) . The acceptance of xenogeneic islet grafts in mice is also dependent on iNKT cells (23) . iNKT cells therefore appear to enhance transplanted islet syngeneic graft and xenograft survival.
Previously, we showed that ␣-GalCer treatment prolongs graft function significantly in newly diagnosed diabetic NOD recipients of syngeneic islet transplants (15) . Since a recurrent autoimmune response in islet graft recipients may be prevented by treatment with IL-4 and IL-10 (24), we determined whether IL-4 and/or IL-10 mediates the ability of ␣-GalCer-activated iNKT cells to prolong syngeneic islet graft survival and prevent recurrent type 1 diabetes. While islet grafts failed in 90% of control vehicle-treated NOD spontaneous diabetic recipients by day 8 posttransplantation, grafts in 90% of ␣-GalCertreated NOD mice were still functional at this time, as evidenced by the maintenance of euglycemia (Fig. 4A) . In contrast, treatment of newly diagnosed NOD.IL-4 -/-diabetic mice treated with ␣-GalCer did not prolong graft function in islet transplant recipients compared with vehicle-treated NOD.IL-4 -/-diabetic mice (Fig. 4B) . Moreover, whereas 100% of islet grafts failed by day 12 posttransplantation in all vehicle-treated NOD and NOD.IL-4 -/-mice and ␣-GalCer-treated NOD.IL-4 -/-mice, islet grafts survived as long as 25 days in ϳ40% of ␣-GalCer-treated NOD mice (Fig. 4A) . However, the lack of IL-4 expression does not accelerate graft rejection, and syngeneic islet grafts sur- (Fig. 4C) . Some ␣-GalCer-treated NOD.IL-10 -/-mice with functional islet grafts had to be sacrificed due to the development of colitis. Removal of grafts in NOD and NOD.IL-10 -/-mice with long surviving grafts resulted in a prompt return to a hyperglycemic state (Fig. 5A and B) , which indicated that the maintenance of euglycemia in ␣-GalCer-treated diabetic recipient mice is islet graft dependent. Thus, ␣-GalCer-prolonged syngeneic islet graft function occurs in an IL-4 -dependent and IL-10 -independent manner. -/-mice were transplanted with islets, treated with ␣-GalCer (n ‫؍‬ 6) or vehicle (n ‫؍‬ 4), and monitored for their BGLs as described in A and B above.
FIG. 5. Maintenance of euglycemia in ␣-GalCer-treated diabetic recipient mice is islet graft dependent. Removal of grafts in ␣-GalCertreated NOD (A) and NOD.IL-10
-/-(B) mice with long surviving grafts resulted in a prompt return to a hyperglycemic state. Unilateral nephrectomy to remove the grafts from mice treated with ␣-GalCer (see Fig. 2A and C) is denoted by narrows.
iNKT PROTECTION FROM TYPE 1 DIABETES BY IL-4 treated NOD.IL-4
Ϫ/Ϫ and -NOD.IL-10 -/-mice were very similar to those from vehicle-treated control mice, with the exception that IL-11 gene expression was decreased in NOD.IL-4 Ϫ/Ϫ mice ( Table 2 ). NOD.IL-10 -/-mice displayed increased IL-6R, MDC, MCP-2, and TGF-␤ expression when compared with NOD mice ( Table 2 ). Given that IL-11 and TGF-␤ elicit protection against type 1 diabetes ( [25] [26] [27] and that SDF-1/CXCR4 interaction and LT-␤ mediate the development of type 1 diabetes (28, 29) , our data suggest that the ␣-GalCer-mediated protection seen in NOD.IL-10 -/-mice may be due to the increased expression of TGF-␤. Elevated TGF-␤ expression may compensate for deficient IL-10 expression and thus decrease the incidence of type 1 diabetes. On the other hand, decreased expression of IL-11 and increased expression of SDF-1/CXCR4 and LT-␤ may be associated with deficient IL-4 expression and contribute to the requirement of IL-4 in ␣-GalCermediated protection from type 1 diabetes. IL-4 and IL-10 are not required for the expansion or survival of iNKT cells. To determine whether IL-4 or IL-10 is required for ␣-GalCer to promote the expansion and/or survival of iNKT cells in secondary lymphoid organs, we examined the frequency of iNKT cells in the spleen and PLNs of ␣-GalCer-treated and -untreated NOD.IL-4 -/-and NOD.IL-10 -/-mice. iNKT cells were tracked by double-staining with an anti-TCR␤ mAb and CD1d tetramers loaded with ␣-GalCer (15). The frequencies of iNKT cells in the spleen and PLNs of wild-type NOD and all three knockout NOD mouse strains were increased significantly after 8 days of ␣-GalCer treatment compared with the frequencies observed in vehicle-treated mice (P Ͻ 0.01). However, no significant differences were observed in the frequencies of iNKT cells in the spleens of the ␣-GalCer-treated wild-type and cytokine knockout NOD mice ( Table 1 , experiment 1). Whereas ␣-GalCer stimulated about a twofold increase in the frequency of iNKT cells in the PLN of NOD.IL-4 -/-mice relative to that in NOD.IL-10 -/-and wild-type NOD mice, the frequencies observed in NOD and NOD.IL-10 -/-mice were similar (P Ͼ 0.05). No significant differences were detected in the spleen and PLNs of vehicle-treated mice (Table 1 , experiment 1). Similar frequencies of iNKT cells were also found in the spleen and PLNs of NOD and NOD.IL-10 -/-mice at 30 days after CY and ␣-GalCer treatment (Table 1, Total RNA was extracted from the PLNs of ␣-GalCer-or vehicle-treated mice and was used to analyze gene expression by GEArray. A greater than twofold change in both two separate experiments was considered significant. The average expression value was shown. NS, less than a twofold change.
maintain iNKT cell homeostasis (30), IL-4 and IL-10 do not appear to be required for ␣-GalCer-induced iNKT cell expansion and/or survival.
DISCUSSION
This study provides direct evidence for the requirement of IL-4 but not IL-10 in the protection against spontaneous type 1 diabetes and prolongation of syngeneic islet graft function by ␣-GalCer-activated iNKT cells. In the case of IL-10, this observation is consistent with the preliminary results of a recent report that IL-10 may not be necessary for iNKT-mediated protection against type 1 diabetes induced by transfer of diabetogenic BDC2.5 T-cells to V␣14C␣ -/-NOD mice (31) . Curiously, a deficiency of V␣14 ϩ iNKT cells in CD1d-deficient NOD mice is causally linked to the induction of type 1 diabetes, and yet this V␣14 ϩ iNKT cell deficiency does not alter the Th1 and Th2 cytokine profiles in these mice (14) . Moreover, an accelerated accumulation of CCR4 ϩ diabetogenic T-cells in pancreatic islets is associated with V␣14 ϩ iNKT cell dysfunction, indicating that V␣14 ϩ iNKT cells may have another important role in the prevention of autoaggressive T-cell recruitment to sites of inflammation (32) . It is noteworthy that mature myeloid CD8␣ -dendritic cells (DCs) accumulate in the PLNs only after treatment with ␣-GalCer, and that this accumulation protects against type 1 diabetes. Transfer of these myeloid DCs into NOD mice significantly protects them against type 1 diabetes (17). Therefore, an immunoregulatory role for V␣14 ϩ iNKT cells in the recruitment of tolerogenic myeloid DCs (CD8␣ -myeloid DC) to PLN, rather than a Th1/Th2 cytokine imbalance, is suggested (14, 17) .
Unexpectedly, our findings appear to differ from our previous report that neutralization of IL-10 activity by an anti-IL-10R antibody in vivo abrogates the protective effect of ␣-GalCer in CY-induced type 1 diabetes (15) . One explanation for this difference may be that the timing of anti-IL-10R administration or production of IL-10 may differ during the development of type 1 diabetes, as reflected by an altered biological activity of IL-10 in vivo. Another explanation is that IL-10 can exhibit seemingly paradoxical effects on susceptibility to type 1 diabetes in NOD mice. Systemic treatment of young NOD mice with IL-10 protects against type 1 diabetes (33,34). In contrast, anti-IL-10 mAb treatment of young NOD mice reduces the severity of insulitis (35) . Whereas BALB/c mice that express an IL-10 transgene in their islet ␤-cells do not develop type 1 diabetes, NOD.IL-10 mice that express an IL-10 transgene in islet ␤-cells develop type 1 diabetes at an accelerated rate (36, 37) . IL-10 contributes early to the pathology of type 1 diabetes via a CD8 ϩ T-cell-dependent pathway, as anti-CD8 antibody-mediated depletion of CD8 ϩ T-cells inhibits the onset of type 1 diabetes without attenuating the severity of insulitis (38) . In addition, IL-10 can also block the regulatory activity in vitro of a CD3 ϩ CD4 -CD8 -T-cell subset (39) , amplify CD4 ϩ T-cell production of the islet ␤-cell destructive IFN-␥ and TNF-␣ cytokines (40) , exacerbate graft rejection (41) (42) (43) , and mediate the development of certain autoimmune lymphoproliferative disorders (37, 44, 45) . These sets of findings raise the possibilities that IL-10 may inhibit and/or delete activated regulatory T-cells, such as iNKT cells, and that a lack of IL-10 expression in NOD.IL-10 Ϫ/Ϫ mice may enhance the level of protection from type 1 diabetes induced by iNKT cell activation. Further experimentation is required to test these possibilities.
In addition, our cDNA array data indicate that the increased level of TGF-␤ gene expression in the PLNs of ␣-GalCer-treated NOD.IL-10 -/-mice compared with ␣-GalCer-or vehicle-treated NOD and NOD.IL-4 -/-mice may be responsible for the protection observed in these mice. Consistent with our findings in IL-10 -deficient NOD mice, Sturlan et al. (46) observed increased plasma levels of TGF-␤ in IL-10 -deficient mice when studying colitis. Recently, a role for TGF-␤ in NKT cell function was described, as Gansuvd et al. (47) demonstrated that rhesus NKT cells can secrete large amounts of TGF-␤ and are in a semianergic state that leads to polarization toward a Th3 regulatory cell phenotype with regulatory/suppressive function in vitro. It is interesting that we observed a greater increase in TGF-␤ gene expression in IL-10 -deficient NOD mice relative to NOD mice after ␣-GalCerinduced iNKT activation, which suggests that activated iNKT cells might overexpress TGF-␤ in the absence of IL-10 expression. This may be explained by the observation that IL-10 and TGF-␤ tend to be cosecreted at sites of inflammation. A study by Kitani et al. (48) using intranasal administration of a TGF-␤-encoding plasmid showed that while TGF-␤ rapidly induces IL-10 production, IL-10 does not induce the secretion of TGF-␤, suggesting that these two cytokines might be coordinately regulated. Thus, in ␣-GalCer-treated NOD.IL-10 -/-mice, an increase in TGF-␤ expression in the PLNs may either compensate for the absence of expression of IL-10 or may be the result of a lack of negative regulation induced by the cytokine. In contrast, in ␣-GalCer-treated NOD.IL-4 -/-mice, a diminished level of IL-11 expression is detectable and no compensatory effect of TGF-␤ in the PLNs is apparent. This may explain why ␣-GalCer-treated NOD.IL-4 -/-mice are not protected from type 1 diabetes and further supports the notion that ␣-GalCer-mediated protection is IL-4 dependent.
A recent report demonstrated that CXCR5/BLC and CCR7/MDC interactions are crucial factors in the development of autoimmunity (49, 50) . We found that expression of CXCR5, BLC, CCR7, and MDC are elevated in vehicletreated NOD.IL-4 -/-and NOD.IL-10 -/-mice compared with vehicle-treated NOD mice. Nonetheless, we did not observe any accelerated onset of spontaneous type 1 diabetes in these mice. On the other hand, complete protection was obtained in ␣-GalCer-treated NOD.IL-10 -/-mice. Thus, it is possible that increased CXCR5/BLC and CCR7/ MDC interactions do not mediate the lack of protection from type 1 diabetes in ␣-GalCer-treated NOD.IL-4 -/-mice. Our observations also differ from the result that ␣-GalCer is unable to protect B6.IL-4 -/-and B6.IL-10 -/-mice against experimental autoimmune encephalomyelitis (51). Therefore, the mechanism of iNKT cell-dependent protection from different autoimmune diseases may depend on the genetic background in which a given disease develops.
In new onset diabetic NOD mice, the grafting of syngeneic islets in the renal subcapsular area restores euglycemia. However, due to a recurrent autoimmune response, the graft is rejected within 10 days of transplantation and iNKT PROTECTION FROM TYPE 1 DIABETES BY IL-4 hyperglycemia returns. Renal subcapsular islet grafts in NOD mice are infiltrated predominantly by Th1 cells, and various types of immunomodulation (e.g., treatment with IL-4, CFA, or insulin) elicit a Th1-to Th2-type shift and suppress recurrent type 1 diabetes (2). Here we show that ␣-GalCer-prolonged syngeneic islet graft function occurs in an IL-4 -dependent and IL-10 -independent manner, similar to the ability of IL-4 but not IL-10 to mediate ␣-GalCer-induced protection against spontaneous type 1 diabetes. Thus, due to these differential cytokine requirements, activated iNKT cells may operate via different mechanisms to restore tolerance during the development of spontaneous and recurrent type 1 diabetes.
